Targeted Treatment of Non-Small Cell Lung Cancer: Focus on Capmatinib with Companion Diagnostics

References

• Drilon A, Cappuzzo F, Ou S-HI, Camidge DR. Targeting MET in lung cancer: will expectations finally be MET? J Thorac Oncol. 2017;12(1):15–26. doi:10.1016/j.jtho.2016.10.014
   PubMed Web of Science ®Google Scholar
• Foundation medicine receives FDA approval for FoundationOne®CDx as the companion diagnostic for tabrectaTM (capmatinib), the only FDA-approved MET inhibitor for patients with metastatic non-small cell lung cancer with METex14. Available from: https://www.foundationmedicine.com/press-releases/0f19426e-6c6b-4d75-8801-789b6f603eb2. Accessed November 6, 2021.
   Google Scholar
• Organ SL, Tsao M-S. An overview of the c-MET signaling pathway. Ther Adv Med Oncol. 2011;3(1 Suppl):S7–S19. doi:10.1177/1758834011422556
   PubMedGoogle Scholar
• Sierra JR, Tsao M-S. c-MET as a potential therapeutic target and biomarker in cancer. Ther Adv Med Oncol. 2011;3(1 Suppl):S21–S35. doi:10.1177/1758834011422557
   PubMedGoogle Scholar
• Zhang Y, Xia M, Jin K, et al. Function of the c-Met receptor tyrosine kinase in carcinogenesis and associated therapeutic opportunities. Mol Cancer. 2018;17(1):45. doi:10.1186/s12943-018-0796-y
   PubMed Web of Science ®Google Scholar
• Pilotto S, Gkountakos A, Carbognin L, Scarpa A, Tortora G, Bria E. MET exon 14 juxtamembrane splicing mutations: clinical and therapeutical perspectives for cancer therapy. Ann Transl Med. 2017;5(1):2. doi:10.21037/atm.2016.12.33
   PubMed Web of Science ®Google Scholar
• Onozato R, Kosaka T, Kuwano H, Sekido Y, Yatabe Y, Mitsudomi T. Activation of MET by gene amplification or by splice mutations deleting the juxtamembrane domain in primary resected lung cancers. J Thorac Oncol. 2009;4(1):5–11. doi:10.1097/JTO.0b013e3181913e0e
   PubMed Web of Science ®Google Scholar
• Davies KD, Lomboy A, Lawrence CA, et al. DNA-based versus RNA-based detection of MET exon 14 skipping events in lung cancer. J Thorac Oncol. 2019;14(4):737–741. doi:10.1016/j.jtho.2018.12.020
   PubMed Web of Science ®Google Scholar
• Drilon A. MET exon 14 alterations in lung cancer: exon skipping extends half-life. Clin Cancer Res. 2016;22(12):2832–2834. doi:10.1158/1078-0432.CCR-16-0229
   PubMed Web of Science ®Google Scholar
• Noonan SA, Berry L, Lu X, et al. Identifying the appropriate FISH criteria for defining MET copy number-driven lung adenocarcinoma through oncogene overlap analysis. J Thorac Oncol. 2016;11(8):1293–1304. doi:10.1016/j.jtho.2016.04.033
   PubMed Web of Science ®Google Scholar
• Vuong HG, Ho ATN, Altibi AMA, Nakazawa T, Katoh R, Kondo T. Clinicopathological implications of MET exon 14 mutations in non-small cell lung cancer - A systematic review and meta-analysis. Lung Cancer Amst Neth. 2018;123:76–82. doi:10.1016/j.lungcan.2018.07.006
   PubMed Web of Science ®Google Scholar
• Go H, Jeon YK, Park HJ, Sung S-W, Seo J-W, Chung DH. High MET gene copy number leads to shorter survival in patients with non-small cell lung cancer. J Thorac Oncol. 2010;5(3):305–313. doi:10.1097/JTO.0b013e3181ce3d1d
   PubMed Web of Science ®Google Scholar
• Guo B, Cen H, Tan X, Liu W, Ke Q. Prognostic value of MET gene copy number and protein expression in patients with surgically resected non-small cell lung cancer: a meta-analysis of published literatures. Coleman WB, ed. PLoS One. 2014;9(6):e99399. doi:10.1371/journal.pone.0099399
   PubMed Web of Science ®Google Scholar
• Awad MM, Oxnard GR, Jackman DM, et al. MET exon 14 mutations in non-small-cell lung cancer are associated with advanced age and stage-Dependent MET genomic amplification and c-Met overexpression. J Clin Oncol. 2016;34(7):721–730. doi:10.1200/JCO.2015.63.4600
   PubMed Web of Science ®Google Scholar
• Liu X, Jia Y, Stoopler MB, et al. Next-generation sequencing of pulmonary sarcomatoid carcinoma reveals high frequency of actionable MET gene mutations. J Clin Oncol. 2016;34(8):794–802. doi:10.1200/JCO.2015.62.0674
   PubMed Web of Science ®Google Scholar
• Schrock AB, Frampton GM, Suh J, et al. Characterization of 298 patients with lung cancer harboring MET exon 14 skipping alterations. J Thorac Oncol. 2016;11(9):1493–1502. doi:10.1016/j.jtho.2016.06.004
   PubMed Web of Science ®Google Scholar
• Schildhaus H-U, Schultheis AM, Rüschoff J, et al. MET amplification status in therapy-naïve adeno- and squamous cell carcinomas of the lung. Clin Cancer Res. 2015;21(4):907–915. doi:10.1158/1078-0432.CCR-14-0450
   PubMed Web of Science ®Google Scholar
• Cappuzzo F, Jänne PA, Skokan M, et al. MET increased gene copy number and primary resistance to gefitinib therapy in non-small-cell lung cancer patients. Ann Oncol. 2009;20(2):298–304. doi:10.1093/annonc/mdn635
   PubMed Web of Science ®Google Scholar
• Tong JH, Yeung SF, Chan AWH, et al. MET amplification and exon 14 splice site mutation define unique molecular subgroups of non-small cell lung carcinoma with poor prognosis. Clin Cancer Res. 2016;22(12):3048–3056. doi:10.1158/1078-0432.CCR-15-2061
   PubMed Web of Science ®Google Scholar
• Ali A, Goffin JR, Arnold A, Ellis PM. Survival of patients with non-small-cell lung cancer after a diagnosis of brain metastases. Curr Oncol Tor Ont. 2013;20(4):e300–306. doi:10.3747/co.20.1481
   PubMed Web of Science ®Google Scholar
• Awad MM, Leonardi GC, Kravets S, et al. Impact of MET inhibitors on survival among patients with non-small cell lung cancer harboring MET exon 14 mutations: a retrospective analysis. Lung Cancer Amst Neth. 2019;133:96–102. doi:10.1016/j.lungcan.2019.05.011
   PubMed Web of Science ®Google Scholar
• Liu X, Wang Q, Yang G, et al. A novel kinase inhibitor, INCB28060, blocks c-MET-dependent signaling, neoplastic activities, and cross-talk with EGFR and HER-3. Clin Cancer Res. 2011;17(22):7127–7138. doi:10.1158/1078-0432.CCR-11-1157
   PubMed Web of Science ®Google Scholar
• Baltschukat S, Engstler BS, Huang A, et al. Capmatinib (INC280) is active against models of non-small cell lung cancer and other cancer types with defined mechanisms of MET activation. Clin Cancer Res. 2019;25(10):3164–3175. doi:10.1158/1078-0432.CCR-18-2814
   PubMed Web of Science ®Google Scholar
• TABRECTATM (capmatinib) tablets, for oral use. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213591s000lbl.pdf. Accessed November 6, 2021.
   Google Scholar
• Lara MS, Holland WS, Chinn D, et al. Preclinical evaluation of MET inhibitor INC-280 with or without the epidermal growth factor receptor inhibitor erlotinib in non-small-cell lung cancer. Clin Lung Cancer. 2017;18(3):281–285. doi:10.1016/j.cllc.2016.11.006
   PubMed Web of Science ®Google Scholar
• Shaker ME, Shaaban AA, El-Shafey MM, El-Mesery ME. The selective c-Met inhibitor capmatinib offsets cisplatin-nephrotoxicity and doxorubicin-cardiotoxicity and improves their anticancer efficacies. Toxicol Appl Pharmacol. 2020;398:115018. doi:10.1016/j.taap.2020.115018
   PubMed Web of Science ®Google Scholar
• Schuler M, Berardi R, Lim W-T, et al. Molecular correlates of response to capmatinib in advanced non-small-cell lung cancer: clinical and biomarker results from a phase I trial. Ann Oncol. 2020;31(6):789–797. doi:10.1016/j.annonc.2020.03.293
   PubMed Web of Science ®Google Scholar
• Bang Y, Su W, Schuler M, et al. Phase 1 study of capmatinib in MET‐positive solid tumor patients: dose escalation and expansion of selected cohorts. Cancer Sci. 2020;111(2):536–547. doi:10.1111/cas.14254
   PubMed Web of Science ®Google Scholar
• Wolf J, Seto T, Han J-Y, et al. Capmatinib in MET exon 14-mutated or MET-amplified non-small-cell lung cancer. N Engl J Med. 2020;383(10):944–957. doi:10.1056/NEJMoa2002787
   PubMed Web of Science ®Google Scholar
• Morris TA, Khoo C, Solomon BJ. Targeting ROS1 rearrangements in non-small cell lung cancer: crizotinib and newer generation tyrosine kinase inhibitors. Drugs. 2019;79(12):1277–1286. doi:10.1007/s40265-019-01164-3
   PubMed Web of Science ®Google Scholar
• Choi W, Park S-Y, Lee Y, et al. The clinical impact of capmatinib in the treatment of advanced non-small cell lung cancer with MET exon 14 skipping mutation or gene amplification. Cancer Res Treat. 2021;53(4):1024–1032. doi:10.4143/crt.2020.1331
   PubMed Web of Science ®Google Scholar
• Dagogo-Jack I, Moonsamy P, Gainor JF, et al. A phase 2 study of capmatinib in patients with MET-altered lung cancer previously treated with a MET inhibitor. J Thorac Oncol. 2021;16(5):850–859. doi:10.1016/j.jtho.2021.01.1605
   PubMed Web of Science ®Google Scholar
• FoundationOne®Liquid CDx. Available from: https://www.foundationmedicine.com/test/foundationone-liquid-cdx. Accessed November 6, 2021.
   Google Scholar
• Johnston KM, Sheffield BS, Yip S, Lakzadeh P, Qian C, Nam J. Comprehensive genomic profiling for non-small-cell lung cancer: health and budget impact. Curr Oncol Tor Ont. 2020;27(6):e569–e577. doi:10.3747/co.27.5995
   PubMed Web of Science ®Google Scholar
• Inagaki C, Maeda D, Hatake K, et al. Clinical utility of next-generation sequencing-based panel testing under the universal health-care system in Japan: a retrospective analysis at a single university hospital. Cancers. 2021;13(5):1121. doi:10.3390/cancers13051121
   PubMed Web of Science ®Google Scholar
• Takeda M, Takahama T, Sakai K, et al. Clinical application of the FoundationOne CDx assay to therapeutic decision-making for patients with advanced solid tumors. Oncologist. 2021;26(4):e588–e596. doi:10.1002/onco.13639
   PubMed Web of Science ®Google Scholar
• Sharaf R, Pavlick DC, Frampton GM, et al. FoundationOne CDx testing accurately determines whole arm 1p19q codeletion status in gliomas. Neuro-Oncol Adv. 2021;3(1):vdab017. doi:10.1093/noajnl/vdab017
   PubMedGoogle Scholar
• Kawaji H, Kubo M, Yamashita N, et al. Comprehensive molecular profiling broadens treatment options for breast cancer patients. Cancer Med. 2021;10(2):529–539. doi:10.1002/cam4.3619
   PubMed Web of Science ®Google Scholar
• Kimura R, Ohtsuka T, Kubo M, et al. FoundationOne® CDx gene profiling in Japanese pancreatic ductal adenocarcinoma patients: a single-institution experience. Surg Today. 2021;51(4):619–626. doi:10.1007/s00595-020-02123-2
   PubMed Web of Science ®Google Scholar
• Wu Y-L, Zhang L, Kim D-W, et al. Phase Ib/II study of capmatinib (INC280) plus gefitinib after failure of epidermal growth factor receptor (EGFR) inhibitor therapy in patients with EGFR-mutated, MET factor-dysregulated non-small-cell lung cancer. J Clin Oncol. 2018;36(31):3101–3109. doi:10.1200/JCO.2018.77.7326
   PubMed Web of Science ®Google Scholar
• Lyudmila Bazhenova, Joshua Bauml, Benjamin Levy. MET Inhibitors in NSCLC: Toxicity Management. Presented at: April 19, 2019; OncLive. Available from: https://www.onclive.com/view/met-inhibitors-in-nsclc-toxicity-management.
   Google Scholar
• Safety, dosing, and administration tabrecta. Available from: https://www.hcp.novartis.com/siteassets/tabrecta/tabrecta-hcp-safety-dosing-guide.pdf. Accessed November 6, 2021.
   Google Scholar
• Study of capmatinib efficacy in comparison with docetaxel in previously treated participants with non-small cell lung cancer harboring MET exon 14 skipping mutation (GeoMETry-III). Available from: https://clinicaltrials.gov/ct2/show/NCT04427072. Accessed November 6, 2021.
   Google Scholar
• Gautschi O, Menon R, Bertrand M, Murer C, Diebold J. Capmatinib and osimertinib combination therapy for EGFR-mutant lung adenocarcinoma. J Thorac Oncol. 2020;15(1):e13–e15. doi:10.1016/j.jtho.2019.07.027
   PubMed Web of Science ®Google Scholar
• Study evaluating efficacy and safety of capmatinib in combination with osimertinib in adult subjects with non-small cell lung cancers as second line therapy (GEOMETRY-E). Available from: https://clinicaltrials.gov/ct2/show/NCT04816214. Accessed November 6, 2021.
   Google Scholar
• Tan DS-W, Leighl NB, Riely GJ, et al. Safety and efficacy of nazartinib (EGF816) in adults with EGFR-mutant non-small-cell lung carcinoma: a multicentre, open-label, phase 1 study. Lancet Respir Med. 2020;8(6):561–572. doi:10.1016/S2213-2600(19)30267-X
   PubMed Web of Science ®Google Scholar
• Jia Y, Juarez J, Li J, et al. EGF816 exerts anticancer effects in non-small cell lung cancer by irreversibly and selectively targeting primary and acquired activating mutations in the EGF receptor. Cancer Res. 2016;76(6):1591–1602. doi:10.1158/0008-5472.CAN-15-2581
   PubMed Web of Science ®Google Scholar
• Study of safety and efficacy of EGFR-TKI EGF816 in combination with cMET inhibitor INC280 in non-small cell lung cancer patients with EGFR mutation. Available from: https://www.clinicaltrials.gov/ct2/show/study/NCT02335944. Accessed November 6, 2021.
   Google Scholar
• Li H, Li C-W, Li X, et al. MET inhibitors promote liver tumor evasion of the immune response by stabilizing PDL1. Gastroenterology. 2019;156(6):1849–1861.e13. doi:10.1053/j.gastro.2019.01.252
   PubMed Web of Science ®Google Scholar
• Felip E. Efficacy and safety of capmatinib plus nivolumab in pretreated patients with EGFR wild-type non–small cell lung cancer. Poster presented at the: 2020 World Conference on Lung Cancer; January 28; 2021; IASLC. Available from: https://library.iaslc.org/conference-program?product_id=20&author=&category=&date=&session_type=&session=&presentation=&keyword=capmatinib&cme=undefined&.
   Google Scholar
• Study of capmatinib and spartalizumab/placebo in advanced NSCLC patients with MET exon 14 skipping mutations. Available from: https://www.clinicaltrials.gov/ct2/show/NCT04323436. Accessed November 6, 2021.
   Google Scholar
• Safety and efficacy of capmatinib (INC280) plus pembrolizumab vs pembrolizumab alone in NSCLC with PD-L1≥ 50%. Available from: https://clinicaltrials.gov/ct2/show/study/NCT04139317. Accessed November 6, 2021.
   Google Scholar
• Drilon A, Clark JW, Weiss J, et al. Antitumor activity of crizotinib in lung cancers harboring a MET exon 14 alteration. Nat Med. 2020;26(1):47–51. doi:10.1038/s41591-019-0716-8
   PubMed Web of Science ®Google Scholar
• Camidge DR, Otterson GA, Clark JW, et al. Crizotinib in patients with MET-amplified NSCLC. J Thorac Oncol. 2021;16(6):1017–1029. doi:10.1016/j.jtho.2021.02.010
   PubMed Web of Science ®Google Scholar
• D’Arcangelo M, Tassinari D, De Marinis F, et al. P2.01-15 phase II single arm study of CABozantinib in non-small cell lung cancer patients with MET deregulation (CABinMET). J Thorac Oncol. 2019;14(10):S644. doi:10.1016/j.jtho.2019.08.1359
   Web of Science ®Google Scholar
• Paik PK, Felip E, Veillon R, et al. Tepotinib in non–small-cell lung cancer with MET exon 14 skipping mutations. N Engl J Med. 2020;383(10):931–943. doi:10.1056/NEJMoa2004407
   PubMed Web of Science ®Google Scholar
• Wu Y-L, Cheng Y, Zhou J, et al. Tepotinib plus gefitinib in patients with EGFR-mutant non-small-cell lung cancer with MET overexpression or MET amplification and acquired resistance to previous EGFR inhibitor (INSIGHT study): an open-label, phase 1b/2, multicentre, randomised trial. Lancet Respir Med. 2020;8(11):1132–1143. doi:10.1016/S2213-2600(20)30154-5
   PubMed Web of Science ®Google Scholar
• Roth KG, Mambetsariev I, Salgia R. Prolonged survival and response to tepotinib in a non-small-cell lung cancer patient with brain metastases harboring MET exon 14 mutation: a research report. Cold Spring Harb Mol Case Stud. 2020;6(6):a005785. doi:10.1101/mcs.a005785
   PubMed Web of Science ®Google Scholar
• Blanc-Durand F, Alameddine R, Iafrate AJ, et al. Tepotinib efficacy in a patient with non-small cell lung cancer with brain metastasis harboring an HLA-DRB1-MET gene fusion. Oncologist. 2020;25(11):916–920. doi:10.1634/theoncologist.2020-0502
   PubMed Web of Science ®Google Scholar
• Takamori S, Matsubara T, Fujishita T, et al. Dramatic intracranial response to tepotinib in a patient with lung adenocarcinoma harboring MET exon 14 skipping mutation. Thorac Cancer. 2021;12(6):978–980. doi:10.1111/1759-7714.13871
   PubMed Web of Science ®Google Scholar
• FDA grants accelerated approval to tepotinib for metastatic non-small cell lung cancer. Available from: https://www.fda.gov/drugs/drug-approvals-and-databases/fda-grants-accelerated-approval-tepotinib-metastatic-non-small-cell-lung-cancer. Accessed November 6, 2021.
   Google Scholar
• Lu S, Fang J, Li X, et al. Phase II study of savolitinib in patients (pts) with pulmonary sarcomatoid carcinoma (PSC) and other types of non-small cell lung cancer (NSCLC) harboring MET exon 14 skipping mutations (METex14+). J Clin Oncol. 2020;38(15_suppl):9519. doi:10.1200/JCO.2020.38.15_suppl.9519
   Web of Science ®Google Scholar
• Sequist LV, Han J-Y, Ahn M-J, et al. Osimertinib plus savolitinib in patients with EGFR mutation-positive, MET-amplified, non-small-cell lung cancer after progression on EGFR tyrosine kinase inhibitors: interim results from a multicentre, open-label, phase 1b study. Lancet Oncol. 2020;21(3):373–386. doi:10.1016/S1470-2045(19)30785-5
   PubMed Web of Science ®Google Scholar
• Yang J, Zhou Q, Chen H, et al. Abstract CT127: a phase I study of cMET inhibitor bozitinib in patients with advanced NSCLC harboring cMET alterations. Tumor Biology. American Association for Cancer Research; 2020:CT127–CT127. doi:10.1158/1538-7445.AM2020-CT127
   Google Scholar
• Yan SB, Um SL, Peek VL, et al. MET-targeting antibody (emibetuzumab) and kinase inhibitor (merestinib) as single agent or in combination in a cancer model bearing MET exon 14 skipping. Invest New Drugs. 2018;36(4):536–544. doi:10.1007/s10637-017-0545-x
   PubMed Web of Science ®Google Scholar
• Engstrom LD, Aranda R, Lee M, et al. Glesatinib exhibits antitumor activity in lung cancer models and patients harboring MET exon 14 mutations and overcomes mutation-mediated resistance to type I MET inhibitors in nonclinical models. Clin Cancer Res. 2017;23(21):6661–6672. doi:10.1158/1078-0432.CCR-17-1192
   PubMed Web of Science ®Google Scholar
• Reungwetwattana T, Liang Y, Zhu V, Ou S-HI. The race to target MET exon 14 skipping alterations in non-small cell lung cancer: the why, the how, the who, the unknown, and the inevitable. Lung Cancer. 2017;103:27–37. doi:10.1016/j.lungcan.2016.11.011
   PubMed Web of Science ®Google Scholar
• Phase 2 study of MGCD265 in patients with non-small cell lung cancer with activating genetic alterations in MET. Available from: https://clinicaltrials.gov/ct2/show/results/NCT02544633. Accessed November 6, 2021.
   Google Scholar
• Merestinib in non-small cell lung cancer and solid tumors. Available from: https://clinicaltrials.gov/ct2/show/study/NCT02920996. Accessed November 6, 2021.
   Google Scholar
• Camidge DR. CT179 - Telisotuzumab vedotin (teliso-v) monotherapy in patients with previously treated c-Met+ advanced non-small cell lung cancer. Poster presented at the: AACR Annual Meeting 2021; April 10; 2021; IASLC. Available from: https://www.abstractsonline.com/pp8/#!/9325/presentation/5250.
   Google Scholar
• Guo MZ, Marrone KA, Spira A, Freeman K, Scott SC. Amivantamab: a potent novel EGFR/c-MET bispecific antibody therapy for EGFR-mutated non-small cell lung cancer. Oncol Haematol. 2021;17(1):42–47. doi:10.17925/OHR.2021.17.1.42
   Google Scholar
• Scagliotti G, Moro-Sibilot D, Kollmeier J, et al. A randomized-controlled phase 2 study of the MET antibody emibetuzumab in combination with erlotinib as first-line treatment for EGFR mutation–positive NSCLC patients. J Thorac Oncol. 2020;15(1):80–90. doi:10.1016/j.jtho.2019.10.003
   PubMed Web of Science ®Google Scholar
• Rowlands T, Boyapati A, Li S, et al. A phase I/II study of REGN5093, a MET x MET bispecific antibody, in patients with MET-altered advanced non-small cell lung cancer (NSCLC). J Clin Oncol. 2020;38(15_suppl):TPS9628. doi:10.1200/JCO.2020.38.15_suppl.TPS9628
   Google Scholar
• Poulsen TT, Grandal MM, Skartved NJØ, et al. Sym015: a highly efficacious antibody mixture against MET -amplified tumors. Clin Cancer Res. 2017;23(19):5923–5935. doi:10.1158/1078-0432.CCR-17-0782
   PubMed Web of Science ®Google Scholar
• Camidge DR, Janku F, Martinez-Bueno A, et al. Safety and preliminary clinical activity of the MET antibody mixture, Sym015 in advanced non-small cell lung cancer (NSCLC) patients with MET amplification/exon 14 deletion (MET Amp/Ex14∆). J Clin Oncol. 2020;38(15_suppl):9510. doi:10.1200/JCO.2020.38.15_suppl.9510
   Web of Science ®Google Scholar
• Qi J, McTigue MA, Rogers A, et al. Multiple mutations and bypass mechanisms can contribute to development of acquired resistance to MET inhibitors. Cancer Res. 2011;71(3):1081–1091. doi:10.1158/0008-5472.CAN-10-1623
   PubMed Web of Science ®Google Scholar
• Tiedt R, Degenkolbe E, Furet P, et al. A drug resistance screen using a selective MET inhibitor reveals a spectrum of mutations that partially overlap with activating mutations found in cancer patients. Cancer Res. 2011;71(15):5255–5264. doi:10.1158/0008-5472.CAN-10-4433
   PubMed Web of Science ®Google Scholar
• Recondo G, Bahcall M, Spurr LF, et al. Molecular mechanisms of acquired resistance to MET tyrosine kinase inhibitors in patients with MET exon 14–mutant NSCLC. Clin Cancer Res. 2020;26(11):2615–2625. doi:10.1158/1078-0432.CCR-19-3608
   PubMed Web of Science ®Google Scholar
• Rotow JK, Gui P, Wu W, et al. Co-occurring alterations in the RAS–MAPK pathway limit response to MET inhibitor treatment in MET exon 14 skipping mutation-positive lung cancer. Clin Cancer Res. 2020;26(2):439–449. doi:10.1158/1078-0432.CCR-19-1667
   PubMed Web of Science ®Google Scholar
• Suzawa K, Offin M, Lu D, et al. Activation of KRAS mediates resistance to targeted therapy in MET exon 14–mutant non–small cell lung cancer. Clin Cancer Res. 2019;25(4):1248–1260. doi:10.1158/1078-0432.CCR-18-1640
   PubMed Web of Science ®Google Scholar
• Pennacchietti S, Cazzanti M, Bertotti A, et al. Microenvironment-derived HGF overcomes genetically determined sensitivity to anti-MET drugs. Cancer Res. 2014;74(22):6598–6609. doi:10.1158/0008-5472.CAN-14-0761
   PubMed Web of Science ®Google Scholar
• Bahcall M, Sim T, Paweletz CP, et al. Acquired MET D1228V mutation and resistance to MET inhibition in lung cancer. Cancer Discov. 2016;6(12):1334–1341. doi:10.1158/2159-8290.CD-16-0686
   PubMed Web of Science ®Google Scholar
• Mok TSK, Park K, Geater SL, et al. A randomized phase (PH) 2 study with exploratory biomarker analysis of ficlatuzumab (F) a humanized hepatocyte growth factor (HGF) inhibitory MAB in combination with gefitinib (G) versus G in asian patients (PTS) with lung adenocarcinoma (LA). Ann Oncol. 2012;23:ix391. doi:10.1016/S0923-7534(20)33782-0
   Web of Science ®Google Scholar